MedTrace Logo

Safety and Effectiveness of MPCD Therapy on the Treatment of Malignant Pleural Effusion

NCT04131231 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 248

Last updated 2019-10-18

No results posted yet for this study

Summary

This is a prospective, open-label , multicenter randomized controlled trial, with 248 cases in 50 centers planned for a period of 2 years. The aim of the study is to evaluate the safety and effectiveness of microparticles packaging chemotherapeutic drugs (MPCD) therapy on the treatment of malignant pleural effusion (MPE) in patients with advanced lung cancer or breast cancer.

Conditions

Interventions

DRUG

microparticles packaging methotrexate (MPs-MTX)

50ml, intrapleural infusion, day5,6,7,8

DRUG

recombinant human interleukin-2(rhIL-2)

50ml, intrapleural infusion, day5,8,11

Sponsors & Collaborators

  • Peking Union Medical College

    lead OTHER

Principal Investigators

  • Fei Ma, MD · Cancer Hospital Chinese Academy of Medical Science

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-15
Primary Completion
2021-01-15
Completion
2021-06-15

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04131231 on ClinicalTrials.gov